Ezetimibe + Simvastatin
INEGY contains the active substances ezetimibe and simvastatin. INEGY is a medicine used to
lower the level of total cholesterol, "bad" cholesterol (LDL cholesterol) and fatty substances called
triglycerides in the blood. Additionally, INEGY increases the level of "good" cholesterol (HDL cholesterol).
INEGY works through two mechanisms that lower cholesterol levels. The active substance ezetimibe
reduces the absorption of cholesterol in the gut. The active substance simvastatin, which belongs to a
class of medicines called "statins", inhibits the production of cholesterol in the body.
Cholesterol is one of several fatty substances present in the blood. Total cholesterol consists mainly
of LDL cholesterol and HDL cholesterol.
LDL cholesterol is often referred to as "bad" cholesterol because it can accumulate on the walls of
arteries, forming plaques. Eventually, these plaques can cause narrowing of the arteries, resulting in
restricted or blocked blood flow to vital organs, such as the heart and brain. Restricted blood flow can
lead to heart attack or stroke.
HDL cholesterol is often referred to as "good" cholesterol because it helps prevent the accumulation
of bad cholesterol in the arteries and protects against heart disease.
Triglycerides are another type of fat present in the blood that can contribute to an increased risk of
heart disease.
INEGY is used in patients for whom diet alone is not enough to control cholesterol levels. While
taking this medicine, you should follow a cholesterol-lowering diet.
INEGY is used as a supplement to a cholesterol-lowering diet in the following cases:
INEGY does not affect weight loss.
In case of doubt about taking any of the above-mentioned medicines, consult a doctor.
Tell your doctor:
Your doctor should perform a blood test before starting INEGY and during treatment if the patient has any liver problems. The test will assess liver function.
Your doctor may also perform blood tests to assess liver function after starting INEGY.
During therapy, the doctor will closely monitor the patient's health if they have diabetes or are at risk of developing diabetes. The risk of developing diabetes is higher in people who have high blood sugar and fat levels, are overweight, and have high blood pressure.
Tell your doctor about any serious lung diseases.
Avoid taking INEGY and fibrates (certain cholesterol-lowering medicines) at the same time, as no studies have been conducted on the simultaneous use of INEGY and fibrates.
kidney damage, and in very rare cases, death.
The risk of muscle damage is higher when taking higher doses of INEGY, particularly the 10 mg + 80 mg dose. The risk of muscle breakdown is also higher in some patients. Talk to your doctor:
Also, tell your doctor or pharmacist if muscle weakness persists. Additional tests and medications may be necessary to diagnose and treat this condition.
Tell your doctor about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take, including those containing any of the following active substances. Taking INEGY with any of the following medicines may increase the risk of muscle problems (some of which are listed in the "When not to take INEGY" section).
Also, tell your doctor or pharmacist about any other medicines you have taken recently, including those available without a prescription. In particular, tell your doctor:
Also, inform any doctor who prescribes a new medicine that you are taking INEGY.
Grapefruit juice contains one or more components that increase the metabolism of some medicines, including INEGY. Avoid drinking grapefruit juice, as it may increase the risk of muscle problems.
Do not take INEGY if you are pregnant, plan to become pregnant, or think you may be pregnant. If you become pregnant while taking INEGY, stop taking the medicine and contact your doctor immediately. Do not take INEGY while breastfeeding, as it is not known whether the medicine passes into breast milk.
Before taking any medicine, consult a doctor or pharmacist.
Do not expect INEGY to affect driving or using machines. However, consider that some people may experience dizziness after taking INEGY.
INEGY tablets contain sugar - lactose. If you have been diagnosed with intolerance to some sugars, contact your doctor before taking INEGY.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is essentially "sodium-free".
Your doctor will determine the dose of INEGY suitable for you, depending on your current treatment and individual risk.
The tablets do not have a dividing line and should not be divided.
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
Use in adolescents(10 to 17 years old): the recommended dose is 1 tabletof INEGY orally,
once a day (do not exceed the maximum dose of 10 mg + 40 mg once a day).
The dose of INEGY 10 mg + 80 mg is recommended only for adult patients with very high cholesterol levels and a high risk of heart disease, who have not achieved target cholesterol levels with a lower dose.
Take INEGY in the evening. It can be taken with or without food.
If your doctor has prescribed INEGY and another cholesterol-lowering medicine containing the active substance colestyramine or another bile acid sequestrant, take INEGY at least 2 hours before or 4 hours after taking the bile acid sequestrant.
If you have any further questions about taking this medicine, ask your doctor or pharmacist.
Like all medicines, INEGY can cause side effects, although not everybody gets them (see section 2: Important information before taking INEGY).
The following side effects have been reported frequently (may affect up to 1 in 10 people):
The following side effects have been reported infrequently (may affect up to 1 in 100 people):
The following side effects have been reported with an unknown frequency (frequency cannot be estimated from the available data):
Contact your doctor if you experience unexplained muscle weakness, tenderness, or pain. In rare cases, muscle problems can be serious, including muscle breakdown leading to kidney damage; in very
rare cases, death has occurred.
If you experience any side effects, including any not listed in this leaflet, tell your doctor or pharmacist.
Side effects can be reported directly to the Department of Drug Monitoring of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products:
Jerozolimskie Avenue 181C, 02-222 Warsaw, Tel.: + 48 22 49 21 301, Fax: + 48 22 49 21 309,
Website: https://smz.ezdrowie.gov.pl .
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.
Blister packs: store in the original package to protect from moisture and light.
Bottles: store tightly closed to protect from moisture and light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The active substances of INEGY are ezetimibe and simvastatin. Each tablet contains 10 mg of ezetimibe and 10 mg, 20 mg, 40 mg or 80 mg of simvastatin.
The other ingredients are: butylhydroxyanisole, citric acid monohydrate, sodium croscarmellose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, propyl gallate.
INEGY tablets are white or almost white, capsule-shaped, with the inscription "311", "312", "313" or "315",
on one side. The tablets do not have a dividing line and should not be divided.
Pack sizes:
14, 28, collective packaging containing 98 (2 boxes of 49 tablets each) tablets.
Not all pack sizes may be marketed.
Organon Polska Sp. z o.o.
Marszałkowska Street 126/134
00-008 Warsaw
Tel.: + 48 22 105 50 01
organonpolska@organon.com
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Netherlands
Organon Heist bv
Industriepark 30
2220 Heist-op-den-Berg
Belgium
INEGY in Austria, Belgium, Cyprus, the Czech Republic, Denmark, Finland, France, Germany, Greece,
Hungary, Iceland, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal,
Slovakia, Slovenia, Spain, Sweden and the United Kingdom.
Vytorin in Germany, Italy, Portugal and Spain.
Goltor in Germany and Italy.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.